---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024336"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:39:10.877754+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adial Pharmaceuticals FY2025 net loss $8M, cash $5.9M; advancing AD04 toward Phase 3

## Summary
- Net loss of $8.0M in FY2025 vs $13.2M in FY2024, driven by lower R&D and 2024 one-time $4.5M inducement expense.
- Cash and cash equivalents $5.9M as of Dec 31, 2025, up from $3.8M; expected to fund operations into H2 2026.
- Entered collaboration framework with Molteni for European AD04 commercialization; potential value ~$60M if successful.
- Regained Nasdaq minimum bid price compliance on Feb 23, 2026; matter now closed.
- Completed EOP2 meeting with FDA; secured U.S. manufacturing partners Cambrex and Thermo Fisher for late-stage development.

## SEC filing metadata
- accession: 0001213900-26-024336
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/0001213900-26-024336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/ea0280282-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024336
- JSON: https://secwatch.observer/filing/0001213900-26-024336.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024336.txt

## Key facts
- Earnings Releases
  ADIAL PHARMACEUTICALS, INC. reported financial results for the 2025 fiscal year ended December 31, 2025.
  - Period: the 2025 fiscal year ended December 31, 2025
  - Result: reported results
  source text: On March 6, 2026, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”) issued a press release that included financial information for its fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/0001213900-26-024336-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.